The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
Abstract
BACKGROUND.: The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). METHODS.: This multinational, double‐blind, placebo‐controlled trial enrolled 809 men with metastatic HRPC. Patients were randomized 1:1 to receive either atrasentan 10 mg per day or placebo. The primary endpoint was time to disease progression (TTP), which was determined according to radiographic and clinical measures. Analyses of overall survival and changes in biomarkers also were performed. RESULTS.: Atrasentan did not reduce the risk of disease progression relative to placebo (hazards ratio, 0.89; 95% confidence interval, 0.76–1.04; P = .136). Most patients progressed radiographically at the first 12‐week bone scan without concomitant clinical progression. In exploratory analyses, increases from baseline to final bone alkaline phosphatase (BAP) and prostate‐specific antigen (PSA) levels were significantly lower with atrasentan treatment (P < .05 for each). The median time to BAP progression (≥50% increase from nadir) was twice as long with atrasentan treatment (505 days vs 254 days; P < .01). The delay in time to PSA progression did not reach statistical significance. Atrasentan generally was tolerated well, and the most common adverse events associated with treatment were headache, rhinitis, and peripheral edema, reflecting the vasodilatory and fluid‐retention properties of endothelin‐A receptor antagonism. CONCLUSIONS.: Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Endothelin 1 in cancer: biological implications and therapeutic opportunities
Rosanò, L., Spinella, F., & Bagnato, A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3546 · Cited by 348
Metadata
- Authors
- Carducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-10-18
- Volume
- 110
- Issue
- 9
- Pages
- 1959-1966
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2042692879
- Cited by
- 294
- References
- 1
- FWCI
- 27.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer. https://app.cochat.ai/papers/10.1002/cncr.22996
- The paper
- Carducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions. (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer. Cancer. https://doi.org/10.1002/cncr.22996
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.